KEY POINTS

• Effective regulation and governance of the pharmaceutical sector is key to effective delivery of healthcare. In the Greater Mekong Subregion (GMS), substandard or falsified medicines detected in the supply chain are fueling resistance to artemisinin combination therapies, the most effective treatment for falciparum malaria. This resistance is undermining the region’s drive to eliminate malaria as a public health threat by 2030.
• National regulatory agencies (NRAs), who are the gatekeepers of the medical product supply chain, lack the resources needed for effective regulation within their respective jurisdictions.
• International collaboration and the implementation of common standards and activities will help the NRAs increase their capacity and improve regulatory effectiveness, leading to better public health outcomes.
• The Asian Development Bank (ADB) engaged the Centre of Regulatory Excellence (CoRE) at the Duke–National University of Singapore Medical School to assess the capacity gaps in the GMS NRAs. To address the identified needs, CoRE worked with GMS NRAs to develop national capacity development plans and, by comparison of needs, the regional roadmap for regulatory systems strengthening in the GMS.
• To foster ongoing regional collaboration, the Asia Pacific Regional Regulatory Partnership for Malaria Elimination (RRPME) has been established in partnership with ADB, to engage regulatory stakeholders and technical partners to support coordination of regulatory strengthening activities.

GATEKEEPERS OF THE MEDICAL PRODUCT SUPPLY CHAIN

National regulatory agencies (NRAs) are the gatekeepers of the supply chain of medical products such as pharmaceuticals and medical devices. It is through registration with an NRA that a manufacturer brings products to market. Post-marketing surveillance of how those products perform and impact patient safety—including how quality is maintained in storage and distribution, and adverse events associated with their use—also falls under the agency’s remit, as does inspection of manufacturing facilities and regulation of product promotion and advertising. At the same time, the value chain for medical products is becoming increasingly globalized. In pharmaceutical manufacturing, for example, active ingredients may be sourced from multiple countries for medicines production in another, before being globally distributed. A weakness in one part of the supply chain can have adverse consequences for patients thousands of miles away.

When the medical products gatekeeper is weak the population is vulnerable to harm from unregulated supplies, including substandard and falsified (“fake”) medicines and devices, often with links to organized crime.1 This issue affects many countries: the World Health Organization (WHO) estimates that only 30% of NRAs worldwide

are strong enough to provide adequate oversight of the medical product supply chain.\(^2\) In Asia and the Pacific, most NRAs do not have sufficient infrastructure and human capital to perform their gatekeeper role effectively.\(^3\)

Disease control and prevention, already a challenging task in resource-constrained environments, is adversely affected by weak regulation. For example, in Asia and the Pacific as a whole, and the Greater Mekong Subregion (GMS) in particular, NRAs are not yet well equipped to support the elimination of malaria, a goal that governments across the region are committed to achieving by 2030.\(^4\) Unregulated medicines in the supply chain, including fake and substandard medicines, are fueling resistance to artemisinin combination therapies, the key and most effective treatment for malaria. This is undermining the region’s drive to achieve elimination of malaria as a public health threat by 2030. Inadequate resources also impact NRAs’ capacity to provide fast access to new medicines of high public health priority, such as antimalarial medicines.

**GLOBAL TREND TOWARD CONVERGENCE AND MUTUAL RELIANCE**

It is not realistic to expect all NRAs to develop the same capacity to assess medical products, provide reliable product information and effectively implement post-approval surveillance. WHO and well-resourced NRAs are promoting a movement towards convergence of regulatory practices and reliance on each other’s assessments and policies. NRAs are being encouraged and supported to move towards common standards for medical product manufacturing processes and regulatory assessment criteria, so that they can rely on each other’s product registration. Thus, criteria and reports used in one jurisdiction to deem medical products fit for entry into the market can then be accepted by another, without the need to duplicate a large part of the assessment work that underpins the registration process.

For countries to engage with their counterparts to work towards convergence and reliance, they first have to know their own state of play, identify the specific gaps in their registration and surveillance systems and lay out a road map to address them. In the GMS, understanding the state of NRAs and working with them to improve their operations was a key component of the

Asia Development Bank (ADB) Regional Malaria and Other Communicable Disease Threats Trust Fund (RMTF). From October 2015 to December 2017, ADB engaged the Duke–National University of Singapore Medical School’s Centre of Regulatory Excellence (CoRE) to address this gap in knowledge and work with GMS countries to strengthen their regulatory systems, and strengthen the countries’ ability to eliminate malaria.\(^5\)

**MAPPING REGULATORS’ GAPS AND NEEDS**

CoRE developed a regulatory system profiling instrument (RSPI) (Box 1), using available literature and existing instruments including the WHO Global Benchmarking Tool, to map NRA needs and capacity gaps in the GMS.\(^6\)

When NRAs were assessed using the RSPI, common issues and gaps across the countries surveyed emerged. In terms of funding and resources, NRAs have inadequate human capital, information and communication technology (ICT) infrastructure, and quality laboratory services for testing of medicines and medical devices. Common gaps in process governance were quality management systems, inadequate management of conflicts of interest within management, and suboptimal processes for ensuring transparency, accountability and communication. In order to develop staff and improve the competency of the NRA, more formal, structured training is needed, together with diversification of skill sets, greater exposure to best practice from other jurisdictions, and greater alignment with global standards and best practice.

These findings concur with existing evidence on the state of NRAs in the region, which indicates that human resource constraints are exacerbated by insufficient recognition for the skill set involved, lack of exposure to best practices in regulation, and insufficient knowledge to advocate for greater government investment in regulation.\(^7\) NRAs are typically perceived as set apart from the public health system, rather than central to it. This ignores the fact that the regulation of medical products, if properly implemented, protects public health and can generate data that are of integral value to health care delivery systems. In the absence of effective international collaboration, registration of the same product in neighbouring countries is burdened with unnecessary

---


The Regional Roadmap focuses on what is needed for malaria elimination, but it also serves much bigger, over-arching goals of universal health coverage (UHC) and health systems strengthening. The roadmap has three priorities. The first is more effective regulatory processes, and implementing quality management systems. The second is new frameworks to enhance regulatory effectiveness and efficiency (employing fast-track processes for medical products of higher public health need and adopting regulatory work-sharing and joint assessments among NRAs). The third is stronger post-market surveillance and control (through risk-based approaches, improved vigilance activities, and multi-stakeholder collaboration to prevent, detect, and remove substandard and falsified medical products). All of these support UHC and stronger health systems overall, and all require investment in NRAs, especially in human resources and ICT.

A ROAD MAP FOR IMPROVING REGULATION

To address these gaps, CoRE worked with NRAs in the GMS to develop national capacity development plans, and, following a comparison of needs, the Regional Roadmap for Regulatory Systems Strengthening in the GMS, to address common priorities across the countries (Figure 1). Technical partners and funding agencies can use this to identify which of the needs fall within their interests and ensure that they are not overlapping with activities of other partners, whilst the NRAs can use the plans to inform their strategic development, discuss their needs with technical agencies and develop proposals for funding. Nationally, as well as calling for regulatory training, the roadmap takes a holistic approach to regulatory systems strengthening, by promoting better organizational governance and communication with external stakeholders. Regionally, the roadmap enables GMS NRAs and other stakeholders to track wider goals for the region and encourage ongoing progress towards enhanced regulatory capacity.

The Regional Roadmap focuses on what is needed for malaria elimination, but it also serves much bigger, over-arching goals of universal health coverage (UHC) and health systems strengthening. The roadmap has three priorities. The first is more effective regulatory processes, and implementing quality management systems. The second is new frameworks to enhance regulatory effectiveness and efficiency (employing fast-track processes for medical products of higher public health need and adopting regulatory work-sharing and joint assessments among NRAs). The third is stronger post-market surveillance and control (through risk-based approaches, improved vigilance activities, and multi-stakeholder collaboration to prevent, detect, and remove substandard and falsified medical products). All of these support UHC and stronger health systems overall, and all require investment in NRAs, especially in human resources and ICT.

ADB AND STRONGER REGULATORY SYSTEMS

ADB, as part of its remit to invest in the health sector, continues to support its developing member countries to improve pharmaceutical regulation and strengthen their health systems. Under the umbrella of the RMTF, from 2013 to 2018, ADB supported regional capacity development for medical products regulation, including collaboration with WHO to support country reporting into the WHO global database of substandard and falsified medical products.

complications for manufacturers, because different NRAs tend to repeat assessments and inspections already performed by others and tend to impose country-specific requirements, despite the availability of regional regulatory guidelines, such as the Association of Southeast Asia Nations (ASEAN) Common Technical Dossier and Requirements.8

A ROAD MAP FOR IMPROVING REGULATION

To address these gaps, CoRE worked with NRAs in the GMS to develop national capacity development plans, and, following a comparison of needs, the Regional Roadmap for Regulatory Systems Strengthening in the GMS, to address common priorities across the countries (Figure 1). Technical partners and funding agencies can use this to identify which of the needs fall within their interests and ensure that they are not overlapping with activities of other partners, whilst the NRAs can use the plans to inform their strategic development, discuss their needs with technical agencies and develop proposals for funding. Nationally, as well as calling for regulatory training, the roadmap takes a holistic approach to regulatory systems strengthening, by promoting better organizational governance and communication with external stakeholders. Regionally, the roadmap enables GMS NRAs and other stakeholders to track wider goals for the region and encourage ongoing progress towards enhanced regulatory capacity.

The Regional Roadmap focuses on what is needed for malaria elimination, but it also serves much bigger, over-arching goals of universal health coverage (UHC) and health systems strengthening. The roadmap has three priorities. The first is more effective regulatory processes, and implementing quality management systems. The second is new frameworks to enhance regulatory effectiveness and efficiency (employing fast-track processes for medical products of higher public health need and adopting regulatory work-sharing and joint assessments among NRAs). The third is stronger post-market surveillance and control (through risk-based approaches, improved vigilance activities, and multi-stakeholder collaboration to prevent, detect, and remove substandard and falsified medical products). All of these support UHC and stronger health systems overall, and all require investment in NRAs, especially in human resources and ICT.

ADB AND STRONGER REGULATORY SYSTEMS

ADB, as part of its remit to invest in the health sector, continues to support its developing member countries to improve pharmaceutical regulation and strengthen their health systems. Under the umbrella of the RMTF, from 2013 to 2018, ADB supported regional capacity development for medical products regulation, including collaboration with WHO to support country reporting into the WHO global database of substandard and falsified medical products.

complications for manufacturers, because different NRAs tend to repeat assessments and inspections already performed by others and tend to impose country-specific requirements, despite the availability of regional regulatory guidelines, such as the Association of Southeast Asia Nations (ASEAN) Common Technical Dossier and Requirements.8

A ROAD MAP FOR IMPROVING REGULATION

To address these gaps, CoRE worked with NRAs in the GMS to develop national capacity development plans, and, following a comparison of needs, the Regional Roadmap for Regulatory Systems Strengthening in the GMS, to address common priorities across the countries (Figure 1). Technical partners and funding agencies can use this to identify which of the needs fall within their interests and ensure that they are not overlapping with activities of other partners, whilst the NRAs can use the plans to inform their strategic development, discuss their needs with technical agencies and develop proposals for funding. Nationally, as well as calling for regulatory training, the roadmap takes a holistic approach to regulatory systems strengthening, by promoting better organizational governance and communication with external stakeholders. Regionally, the roadmap enables GMS NRAs and other stakeholders to track wider goals for the region and encourage ongoing progress towards enhanced regulatory capacity.

The Regional Roadmap focuses on what is needed for malaria elimination, but it also serves much bigger, over-arching goals of universal health coverage (UHC) and health systems strengthening. The roadmap has three priorities. The first is more effective regulatory processes, and implementing quality management systems. The second is new frameworks to enhance regulatory effectiveness and efficiency (employing fast-track processes for medical products of higher public health need and adopting regulatory work-sharing and joint assessments among NRAs). The third is stronger post-market surveillance and control (through risk-based approaches, improved vigilance activities, and multi-stakeholder collaboration to prevent, detect, and remove substandard and falsified medical products). All of these support UHC and stronger health systems overall, and all require investment in NRAs, especially in human resources and ICT.

ADB AND STRONGER REGULATORY SYSTEMS

ADB, as part of its remit to invest in the health sector, continues to support its developing member countries to improve pharmaceutical regulation and strengthen their health systems. Under the umbrella of the RMTF, from 2013 to 2018, ADB supported regional capacity development for medical products regulation, including collaboration with WHO to support country reporting into the WHO global database of substandard and falsified medical products.

Box 1: The Regulatory System Profiling Instrument

The regulatory system profiling instrument (RSPI) comprises a set of questionnaires, to be completed by the national regulatory agency in a process of self-assessment. The findings are validated by in-country interviews, and supplemented with the results of meetings and group discussions with stakeholders in the regulatory system, including industry and private sector players, the Ministry of Health, and academia.

Designed to be shorter and quicker to use than the World Health Organization (WHO) tool, the RSPI takes only three days to administer and complete. It is largely self-reported, unlike the WHO tool, which requires some documentary verification. However, it uses the same domains as the WHO tool in assessing needs across the following regulatory functions:

- product registration (assessing and authorising products to be on the market based on evidence of efficacy, safety and quality);
- licensing of medical product establishments (assessing and authorising premises where medical products may be manufactured, distributed, and sold);
- inspections of medical product establishments (on-going inspections of medical product establishments to ensure they maintain standards);
- post-marketing surveillance (sampling samples on the market to ensure they are still of good quality and from licensed sources);
- medical product vigilance and pharmacovigilance (assessing the ongoing safety of medical products on the market);
- control of promotion and advertising (overseeing and controlling the means that companies use to promote their medical products); and
- regulatory quality control testing (laboratory support to test the quality of medical products during market authorization and post-marketing surveillance).

The regulatory system profiling instrument (RSPI) comprises a set of questionnaires, to be completed by the national regulatory agency in a process of self-assessment. The findings are validated by in-country interviews, and supplemented with the results of meetings and group discussions with stakeholders in the regulatory system, including industry and private sector players, the Ministry of Health, and academia.

Designed to be shorter and quicker to use than the World Health Organization (WHO) tool, the RSPI takes only three days to administer and complete. It is largely self-reported, unlike the WHO tool, which requires some documentary verification. However, it uses the same domains as the WHO tool in assessing needs across the following regulatory functions:

- product registration (assessing and authorising products to be on the market based on evidence of efficacy, safety and quality);
- licensing of medical product establishments (assessing and authorising premises where medical products may be manufactured, distributed, and sold);
- inspections of medical product establishments (on-going inspections of medical product establishments to ensure they maintain standards);
- post-marketing surveillance (sampling samples on the market to ensure they are still of good quality and from licensed sources);
- medical product vigilance and pharmacovigilance (assessing the ongoing safety of medical products on the market);
- control of promotion and advertising (overseeing and controlling the means that companies use to promote their medical products); and
- regulatory quality control testing (laboratory support to test the quality of medical products during market authorization and post-marketing surveillance).

The regulatory system profiling instrument (RSPI) comprises a set of questionnaires, to be completed by the national regulatory agency in a process of self-assessment. The findings are validated by in-country interviews, and supplemented with the results of meetings and group discussions with stakeholders in the regulatory system, including industry and private sector players, the Ministry of Health, and academia.

Designed to be shorter and quicker to use than the World Health Organization (WHO) tool, the RSPI takes only three days to administer and complete. It is largely self-reported, unlike the WHO tool, which requires some documentary verification. However, it uses the same domains as the WHO tool in assessing needs across the following regulatory functions:

- product registration (assessing and authorising products to be on the market based on evidence of efficacy, safety and quality);
- licensing of medical product establishments (assessing and authorising premises where medical products may be manufactured, distributed, and sold);
- inspections of medical product establishments (on-going inspections of medical product establishments to ensure they maintain standards);
- post-marketing surveillance (sampling samples on the market to ensure they are still of good quality and from licensed sources);
- medical product vigilance and pharmacovigilance (assessing the ongoing safety of medical products on the market);
- control of promotion and advertising (overseeing and controlling the means that companies use to promote their medical products); and
- regulatory quality control testing (laboratory support to test the quality of medical products during market authorization and post-marketing surveillance).

The regulatory system profiling instrument (RSPI) comprises a set of questionnaires, to be completed by the national regulatory agency in a process of self-assessment. The findings are validated by in-country interviews, and supplemented with the results of meetings and group discussions with stakeholders in the regulatory system, including industry and private sector players, the Ministry of Health, and academia.

Designed to be shorter and quicker to use than the World Health Organization (WHO) tool, the RSPI takes only three days to administer and complete. It is largely self-reported, unlike the WHO tool, which requires some documentary verification. However, it uses the same domains as the WHO tool in assessing needs across the following regulatory functions:

- product registration (assessing and authorising products to be on the market based on evidence of efficacy, safety and quality);
- licensing of medical product establishments (assessing and authorising premises where medical products may be manufactured, distributed, and sold);
- inspections of medical product establishments (on-going inspections of medical product establishments to ensure they maintain standards);
- post-marketing surveillance (sampling samples on the market to ensure they are still of good quality and from licensed sources);
- medical product vigilance and pharmacovigilance (assessing the ongoing safety of medical products on the market);
- control of promotion and advertising (overseeing and controlling the means that companies use to promote their medical products); and
- regulatory quality control testing (laboratory support to test the quality of medical products during market authorization and post-marketing surveillance).
falsified medical products. ADB also worked closely with the Myanmar NRA to transform its regulatory system and process (Box 2). This work by ADB in Myanmar serves as a useful case study in how ICT and training can transform an NRA.

ADB has also invested in numerous projects covering integrated information systems for better quality control of the supply chain, improved cross-border coordination, and collaboration between border control, customs and regulatory agencies. In the broader area of ICT in the health sector, ADB has fostered convergence of digital health standards to comply with international information standards, which is crucial for cross-border collaboration and mutual reliance between regulators. ADB’s efforts benefited from working with countries through a multi-dimensional trust fund with a clear remit to tackle malaria and other communicable diseases. The trust fund structure enabled regional, rather than just national, information gathering, and accelerated joint action between national counterparts toward a common goal. It was a catalyst for sustainable results, which ADB is taking forward through its other health-sector projects.

LESSONS LEARNED: HOW TO STRENGTHEN MEDICAL PRODUCT REGULATION

NRAs should be a cornerstone of UHC, but for that goal to be realized, the agencies must be better integrated into the public health system, and be seen by other players as relevant agencies with unique skills and a valuable data set that can be shared for the benefit of other parts of the health system. NRAs need to invest more in people, processes, technology, and communication, and ADB’s experience in the medical regulatory environment points to several key lessons learned in how this can be achieved. First, regional and national digital health standards must be in place so that countries can share data. Second, NRAs need to introduce an integrated regulatory information management system (IRIMS) (Box 3), as was implemented in Myanmar. Third, NRAs are a key part of the global value chain and should be empowered to ensure that this value chain properly serves the population (Figure 2), supports UHC, and promotes regional health security.
In 2017, under the Asian Development Bank (ADB) Regional Malaria and Other Communicable Disease Threats Trust Fund, an ADB consultant was embedded in the Food and Drug Administration (FDA), Myanmar, the country's national regulatory agency. At that time, Myanmar’s medical product registration process relied on a cumbersome, paper-based registration application with some data input into a scanty Excel file. This system was taxing the human resource capacity of the FDA to the limit.

Being embedded within the FDA, the consultant was able not only to develop a deep understanding of how the current system operated, but also to build trust with staff. These proved to be valuable assets when it came time to assist the FDA in addressing its priority needs, and move away from a paper-based process to a fully online system. The consultant was able to secure buy-in for the changes he proposed, and by mid-2018, an online-only product registration application process was in place, including the training of private sector applicants. As part of the process of establishing an integrated regulatory information management system, the FDAs’ online databases were linked to those for the management of facility inspections and of quality control laboratories.

Now the national quality control laboratory and inspectors are able to link to an online database to get the information they need from medicine registration dossiers. Inspectors can use a tablet-based system to connect to the central registration database and find out which products are registered, and to directly upload images and videos of the facilities they are inspecting, along with the inspection reports and follow-up actions.

This online regulatory information management system was developed with open-source software. As all source code is made available to the FDA, hosting the system does not require ownership of a data center and will entail an annual maintenance cost of less than $20,000 after ADB support ends.

The FDA, working with the consultant, also reviewed its list of approved products and compared the listed products with those on the lists used by reference authorities—the European Medicines Agency and the regulatory agencies of Australia, Canada, the United Kingdom, and the United States. The process revealed medicines not registered in any of these reference countries, as well as banned and obsolete products. After this review, the online medicine registration system was set up to automatically trigger an alert whenever products with banned or obsolete active ingredients were submitted for registration. Product information documents, which describe a medicine’s indications, contraindications, dosages, and warnings, will also rely on reference texts obtained from Australia’s Therapeutic Goods Administration and the British National Formulary.

Although such a major change is usually simpler to bring about in a setting like Myanmar, where no complex system is in place, the impact of the ADB project is also being felt elsewhere in Asia. The project attracted the interest of the NRAs in Cambodia, Thailand, the Philippines, and Viet Nam.
An integrated regulatory information management system (IRIMS) is a digital platform that processes, stores, retrieves, and shares information about regulatory activities. It enables effective information exchange, coordination, and implementation across all key medicine regulatory functions, through a permanently established connection. These functions include product registration; company licensing; quality testing; inspection of manufacturers, wholesalers, and retail outlets; monitoring of importations and manufacturing output; and post-marketing monitoring of the quality and safety of medicines. An example of an IRIMS is Myanmar’s online registration database linked to quality control testing and inspection of retail outlets. Key to a successful IRIMS is standardization of terminology as well as the establishment of a unique code (or registration number) assigned to each individual pack size and type for each authorized product. The same approach is used for products authorized for marketing and products admitted through special access schemes such as donations, disease control programs, or compassionate-use programs. The starting point of an IRIMS is invariably the medicine registration database. If this is properly set up, all the other regulatory functions will be able to link to it, obtain data, and complement the database with their own data and output (see figure).

The key benefits of an IRIMS are:

- enhanced capacity to protect public health through faster exchange of information and more efficient regulatory work;
- reduced staff costs, thanks to automation of repetitive tasks such as preparation of letters, certificates, and internal reports;
- increased visibility and credibility of the regulatory authority within the public health community;
- increased capacity to filter out products with inadequate safety, efficacy, or quality documentation; and
- increased capacity to support the work of other government institutions (such as pharmaceutical procurement and distribution programs) by providing timely and reliable data to inform choices and decisions.
Latt, aged 21, lives in a remote area in Myanmar. He has been diagnosed with malaria and has been prescribed medication. The village pharmacy has malaria medicines for sale, but their efficacy or safety is unknown because they did not pass through effective regulatory scrutiny. The medicines used to treat him turn out to be ineffective, and his condition worsens, and the family must find the money to secure another round of treatment and hope that it is more effective. The use of substandard or falsified medication increases the risk of drug-resistant malaria in the region.

Ineffective product registration system managed by understaffed NRA struggles to keep pace with the applications for new product registration. Manufacturers are discouraged from entering the registration process because of uncertainties, time, and costs involved. This hinders the entry of new, good-quality, effective, and affordable medications into the supply chain, and may disrupt the steady supply of high-quality medicines required to treat malaria.

Online product registration system supports low-cost, effective management of product-related information and dossiers. System alerts NRA in case of products with unjustified, obsolete, or banned substances. NRA has identified and established collaboration with other NRAs to avoid duplication of work and exchange information permitting reliance on assessment done by others. Easy access to safe, reliable, and genuine medications filters out substandard and falsified medicines from the supply chain.